David R. Wise, MD, PhD, on Novel Biomarkers in Prostate Cancer: Is Tissue the Issue?

May 31, 2020 By The ASCO Post Staff

David R. Wise, MD, PhD, of New York University Perlmutter Cancer Center, summarizes three important studies in prostate cancer: circulating tumor cell count as a prognostic marker of PSA response and progression in metastatic castration-sensitive disease; new phenotypic subtypes; and how circulating tumor DNA dynamics associate with treatment response and radiologic progression-free survival (Abstracts 5506, 5507, and 5508).

Related Content